E. Ohman J or Asset Management AB Has $7.67 Million Stock Position in DexCom, Inc. $DXCM

E. Ohman J or Asset Management AB boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 49.0% in the 4th quarter, HoldingsChannel reports. The firm owned 115,492 shares of the medical device company’s stock after buying an additional 38,000 shares during the period. E. Ohman J or Asset Management AB’s holdings in DexCom were worth $7,665,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Twin Peaks Wealth Advisors LLC bought a new stake in DexCom during the second quarter worth about $26,000. SJS Investment Consulting Inc. raised its stake in shares of DexCom by 4,800.0% in the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 384 shares during the last quarter. Financial Consulate Inc. bought a new position in shares of DexCom in the third quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of DexCom in the 2nd quarter worth approximately $45,000. Finally, Sound Income Strategies LLC boosted its holdings in shares of DexCom by 83.8% in the 3rd quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after acquiring an additional 285 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of recent analyst reports. Morgan Stanley reaffirmed an “overweight” rating on shares of DexCom in a report on Monday, January 12th. Leerink Partners reissued an “outperform” rating and issued a $92.00 price objective on shares of DexCom in a research note on Tuesday, December 16th. Mizuho increased their target price on DexCom from $78.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, February 13th. Weiss Ratings upgraded DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $85.50.

DexCom Stock Down 1.5%

NASDAQ:DXCM opened at $65.94 on Tuesday. The company has a market cap of $25.38 billion, a price-to-earnings ratio of 31.40, a P/E/G ratio of 1.30 and a beta of 1.48. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. The stock’s fifty day moving average price is $70.40 and its two-hundred day moving average price is $67.93. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.65 by $0.03. The company had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The business’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same period last year, the firm earned $0.45 EPS. On average, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $64.85, for a total value of $110,245.00. Following the completion of the sale, the executive vice president directly owned 112,904 shares in the company, valued at $7,321,824.40. This trade represents a 1.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.32% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.